Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 100 of 110 publications.

Hill N, Mogle J, Kitko L, Bratlee-Whitaker E, Corrente C. Cognitive interviewing in the evaluation of subjective cognitive items with older adults. Presented at the 2017 Alzheimer’s Association International Conference; July 2017. London, England. [abstract] Alzheimers Dement. 2017 Jul; 17(7):P1060. doi: 10.1016/j.jalz.2017.06.1516

Dong O, Li A, Suzuki O, Oni-Orisan A, Stouffer GA, Lee CR, Wiltshire T. Projected impact of adopting a multiplexed preemptive genotyping intervention in cardiac catheterization laboratory patients. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May 1; 20(5):A276.

Herring W, Keenan A, Mauskopf J, Michael T, Wiegand F. The potential economic value of disease-modifying treatments in Alzheimer's disease: patient-level simulation of predementia symptom trajectories. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A12.

Pajouheshnia R, Groenwold R, Moons K, Reitsma J, Peelen L. The effects of treatment use when externally validating a prediction model that did not include treatment as predictor. Presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; February 2016. Birmingham, United Kingdom. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):12. doi: 10.1186/s41512-016-0001-y

Andrews E, Sturmer T, McGrath LJ, Johnson Funk M, Lund JL, Johannes CB, Gilsenan AW, Powers C. Exploring innovative methods to conduct validation using United States Medicare administrative claims data. Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(S3):50.

Margulis AV, Varas-Lorenzo C, Bui CL, McQuay LJ, Ziemiecki R, Reynolds M, Rebordosa C, Pladevall-Vila M, Fortuny J, Rivero-Ferrer E, Plana E, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS). Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.

Ritchey ME, Jalbert J, Gilsenan A, Lystig T, Peng M, Kou TD, Blumentals W. The epidemiological approach to rare disease research: challenges and opportunities. Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(S3):S479.

Danysh H, Zhang K, Mitchell LE, Scheurer ME, Lupo PL. Maternal residential proximity to roadways during pregnancy and childhood central nervous system tumors: a population-based assessment in Texas, 2003-2009. Presented at the 47th Congress of the International Society of Paediatric Oncology; October 10, 2015. Cape Town, South Africa. [abstract] Pediatr Blood Cancer. 2015 Nov; 62(S4). Previously presented at the Brain Tumor Epidemiology Consortium 2015 Annual Conference.

Andrade S, Perez-Gutthann S, Hua W, Kawai A, Martin D, Reichman M, Toh D. Building a sustainable surveillance system to monitor the use and safety of medical products in pregnancy. Presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Sep; 24(S1):239-40. doi: 10.1002/pds.3838

Kawai AT, Jin R, Soumerai S, Vaz LE, Rett M, Lee G. Impact of nonpayment for preventable infections on billing rates for central line associated bloodstream infections and catheter-associated urinary tract infections. Presented at the 2014 Infectious Disease Week Conference; October 10, 2014. Philadelphia, PA. [abstract] Open Forum Infect Dis. 2014 Dec; 1(Suppl_1):S44. doi: 10.1093/ofid/ofu051.118

Danysh HE, Mitchell LE, Zhang K, Scheurer ME, Lupo PL. A statewide assessment of childhood central nervous system tumors and traffic-related air pollution. Presented at the 46th Congress of the International Society of Paediatric Oncology (SIOP); October 2014. Toronto, Canada. [abstract] Pediatr Blood Cancer. 2014 Dec; 61(S2). Previously presented at the Brain Tumor Epidemiology Consortium 2014 Annual Conference. doi: 10.1002/pbc.25314

Basarir H, Pollard D, Brennan A, Elliott J, Heller S, Campbell MJ. The potential value of ongoing support in type-1 diabetes mellitus with dafneplus: exploratory pre-trial cost-effectiveness analysis on proposed trial end-point target for 12-month Hba1c improvement. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A350. doi: 10.1016/j.jval.2014.08.725

Moride Y, Andrews EB, Perez-Gutthann S, Soriano-Gabarró M, Heaton S, Suzart-Woischnik K, Vassilev Z, Raine JM. Challenges in risk minimization evaluation: CIOMS Working Group IX consensus and recent field experience. Presented at the 30th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; October 2014. Taipei, China. [abstract] Pharmacoepidemiol Drug Saf. 2014 Oct; 23(S1):41-2.

Carsin AE, Svanes C, Sunyer J, Dratva J, Norback D, Holm M, Lindbreg E, Benediktsdottir B, Forsberg B, Jogi R, Schlunssen V, Franklin K, Gislason T, Sigsgaard T, Heinrich J, Janson C, Dharmage S, Johannessen A, Real FG. Metabolic phenotypes of parent and grand-parents in relation to asthma in offspring. Presented at the 2014 European Respiratory Society (ERS) Congress; September 6, 2014. Munich, Germany. [abstract] Eur Respir J. 2014 Sep 1; 44(Suppl 58):482.

Lupo PJ, Chi CH, Danysh HE, Scheurer ME, Suzawa H, Woodard TL, Kovanci E, Okcu MF, Gibbons WE. Clinical and genetic predictors of impaired fertility in female survivors of childhood cancer. Presented at the American Society of Preventive Oncology 38th Annual Meeting; March 2014. Arlington, VA. [abstract] Cancer Epidemiol Biomarkers Prev. 2014 Mar; 23:565-6. doi: 10.1158/1055-9965.EPI-14-0072

Casulo C, Byrtek M, Dawson K, Zhou X, Farber CM, Flowers CR. Early relapse of follicular lymphoma after R-CHOP uniquely defines patients at high risk for death: an analysis from the National LymphoCare Study. Presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2013. New Orleans, LA. [abstract] Blood. 2013 Nov; 122(21):510. doi: 10.1182/blood.V122.21.510.510

Warttig S, Elliott N. Partially updating a guideline to improve its implementation. Presented at the G-I-N Conference; August 2013. San Francisco, CA. [abstract] BMJ Qual Saf. 2013; 22(Suppl 1):A32. doi: 10.1136/bmjqs-2013-002293.93

Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA. Clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia: evidence from U.S. hospitals, 2007-2010. Presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):239. doi: 10.1182/blood.V120.21.239.239

Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Carson RT, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing chronic constipation symptom severity and change: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 6; 24(Suppl. s2):180.

Spiegel BMR, Locke G, Kurtz CM, Williams VSL, Nelson LM, Carson RT, Currie MG, Schneier HA, Johnston JM. Clinically meaningful change benchmarks for IBS-C symptoms developed using data from two phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep; 24(s2):35.

Mines D, Tennis PS, Curkendall S, Li A, Peterson C, Andrews EB, Calingaert B, Rothman KJ. Topiramate use in pregnancy and risk of oral clefts. Presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):320. doi: 10.1111/j.1399-5448.2012.03324.x

Martín-Merino E, Fortuny J, Rivero E, García-Rodríguez LA. Risk factors for incident diabetic retinopathy in type II diabetes in UK primary care. Presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; June 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):S3.

Martín-Merino E, Fortuny J, Rivero E, García-Rodríguez LA. Validation of diabetic retinopathy and maculopathy diagnoses recorded in a United Kingdom primary care database. Presented at the 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):S164-5.

Thompson JR, Talbird SE, Mauskopf JA, Brogan AJ, Standaert B. Translating outcomes from a dynamic transmission model for vaccination to cost-effectiveness estimates: the impact of different analytic approaches on the results. Presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A10.

Sinha R, Byrtek M, DeJoubner NJ, Nooka AK, Taylor M, Cerhan JR, Ziemiecki RM. Examining the outcomes of watchful waiting (WW) among US patients with advanced stage follicular lymphoma (FL). Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):775. doi: 10.1182/blood.V118.21.775.775

Kaye JA, Castellsague J, Bui CL, Calingaert B, McQuay L, Riera Guardia N, Saltus CW, Quinlan S, Holick CN, Wahl PM, Rothman KJ, Wallander MA, Perez-Gutthann S. Case screening and validation in a population-based study of antimicrobial use and acute liver injury. Presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 14, 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug 12; 20(S1):S5-6. doi: 10.1002/pds.2206

Herring WL, Herrmann JW. Scheduling impatient jobs with diminishing rewards: the impact of deteriorating survival probabilities on mass casualty incident triage. Presented at the 5th Multidisciplinary International Conference on Scheduling: Theory and Applications (MISTA 2011); August 2011. Phoenix, AZ. [abstract] J Sched. 2011 Aug; 14:587-91.

Nastoupil L, Sinha R, Byrtek M, Taylor M, Cerhan JR, Friedberg J, Ziemiecki RM. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States. Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Jan; 118(21):97. doi: 10.1182/blood.V118.21.97.97

Twiss J, McKenna S, Crawford SR, Doward LC. Scaling properties of two commonly used outcome measures in dermatology – the Dermatology Life Quality Index (DLQI) and the Psoriasis Quality of Life Scale (PSORIQoL). Presented at the 13th Annual European Congress; November 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A244.

Loughlin J, Quinn S, Rivero E, Norman H, Earnes DL, Wong J, Seeger JD. No evidence for association of tegaserod with adverse cardiovascular ischemic events. Presented at the 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug; 18(Suppl 1):S17.

Rothman KJ, Dal Pan G, Evans S, Stang P, Jones J, Sturmer T. The future of epidemiology. Presented at the 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug; 18(Suppl 1):S205.

Wentworth CW, Arellano FM, Rivero E, Pavesi M, Dey D, Arana A. Use of intravitreal (IVT) injection therapies in the general population of the United States of America. Presented at the 24th International Conference on Pharmacoepidemiology; August 2008. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2008 Aug; 17(Suppl 1):S251-2.

Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 21, 2007. Quebec City, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2007 Aug 7; 16(Suppl 2):S55. doi: 10.1002/pds.1461

Seeger JD, Ziyadeh N, Lievano F, Rivero E, Earnest DL, Shetzline M, Holden W, Walker AM. Nested case-control validation of results of the Zelnorm™ epidemiological study. Presented at the 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2006. Lisbon, Portugal. [abstract] Pharmacoepidemiol Drug Saf. 2006 Aug; 15(Suppl 1):S32.

Seeger JD, Quinn S, Lievano F, Rivero E, Earnest DL, Shetzline M, Holden W, Walker AM. No increased risk of abdominal or pelvic surgery associated with tegaserod exposure: the zelnormTM epidemiological study. Presented at the 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management,; August 2006. Lisbon, Portugal. [abstract] Pharmacoepidemiol Drug Saf. 2006 Aug; 15(Suppl 1):S12-3.

Delea T, Hagiwara M, Borker R, Stanford R. Observational study of the risk of ED visit or hospitalization in COPD patients receiving maintenance therapies: a time-dependent analysis. Presented at the 71st Annual Chest International Meeting; October 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 Supplement):178S. doi: 10.1378/chest.128.4_MeetingAbstracts.178S-a

Riedel A, Chastek B, Borker RD. Healthcare and economic burden in undiagnosed chronic obstructive pulmonary disease (COPD) patients. Presented at the 71st Annual Chest International Meeting; October 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 Supplement):123S.

Johannes CB, Chiang CC, Ng EW, Eng PM, Seeger JD, Walker AM. Treatment patterns in patients using biological disease modifying antirheumatic therapy for rheumatoid arthritis. Presented at the 21st International Conference on Pharmacoepidemiology; August 2005. Nashville, TN. [abstract] Pharmacoepidemiol Drug Saf. 2005 Sep; 14(Suppl 2):S195. doi: 10.1002/pds.1136

Cole JA, Johannes CB, Loughlin J, Seeger JD, Velentgas P, Walker AM. Challenges in conducting propensity score matched cohort studies. Presented at the 21st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2005. Nashville, TN. [abstract] Pharmacoepidemiol Drug Saf. 2005 Aug; 14(Suppl 2):S175.

Gimeno V, Castellsague J, Maguire A, Eaton SC, McQuay LJ, Zhou X, Perez-Gutthann S. Gastrointestinal and cardiovascular characterization of users of valdecoxib and other cox-2 specific inhibitors. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(S1):S236.

Arana A, Rivero E, Egberts TCG. What do we show and who does so? An analysis of the abstracts presented at the 19th ICPE. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):s330-1.

Arana A, Arellano FM, Sánchez-Matienzo D, Perez-Gutthann S. Choosing the measure of relative proportional reporting in quantitative analyses of spontaneous reports. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S324.

Maguire A, Arellano Felix M, Perez-Gutthann S, Arana A. Risk benefit modeling: the use of stochastic simulation for safety evaluations. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S272.

Johannes CB, Schneider GA, Walker AM, Viveash D, Wallis WJ. Increased incidence of lymphoma among patients with rheumatic diseases based on automated insurance claims information. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13:S239.

Johannes CB, Schneider GA, Walker AM, Zhao S, Shibata A. Validation of a propensity score developed using claims data in controlling for health status of rheumatic disease patients initiating etanercept compared with other DMARDS. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(S1):S16.

Sanchez-Matienzo D, Castellsague J, Arana A. Effect of control of confounding in the estimation of the proportional reporting ratio. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S225-6.

Leufkens HG, Arana A. Pharmacoepidemiology adds to orphan drug development. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S256-7.

Fischer TL, Borker R, Barnhart F, Morris A, Zhu J. Effect of cilomilast on chronic obstructive pulmonary disease (COPD) patients with impaired quality of life (QOL). Presented at the 69th Annual Chest International Meeting; January 2003. Orlando, FL. [abstract] Chest. 2003 Jan; 124(4 Supplement):129S. doi: 10.1378/chest.124.4_MeetingAbstracts.129S

Sánchez Matienzo D, Gimeno V, Castellsague J, Arana A. A comparative safety profile of serious skin and hypersensitivity reactions: cOX-s specific inhibitors vs. non-selective NSAIDs and other selected drugs. Presented at the 19th International Conference on Pharmacoepidemiology; 2003. [abstract] Pharmacoepidemiol Drug Saf. 2003; 12(S1):S185.

Anthony MS, Clarkson TB. Does extent of pretreatment atherosclerosis influence the effects of conjugated equine estrogens on atherosclerosis progression? Presented at the 51st Annual Scientific Session of the American College of Cardiology; March 17, 2002. Atlanta, GA. [abstract] J Am Coll Cardiol. 2002 Mar; 39:248A.